Cargando…

Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

BACKGROUND: The hypoglycemic effect of bezafibrate is well established, but administration to a large population of patients with diabetes has not been reported. We investigated glycemic control, relationship between lipid metabolism and HbA1c, and safety in diabetic patients treated with bezafibrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teramoto, Tamio, Shirai, Kohji, Daida, Hiroyuki, Yamada, Nobuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342914/ https://www.ncbi.nlm.nih.gov/pubmed/22439599 http://dx.doi.org/10.1186/1475-2840-11-29

Ejemplares similares

Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
por: Teramoto, Tamio, et al.
Publicado: (2013)

Metabolic effects of bezafibrate in mitochondrial disease
por: Steele, Hannah, et al.
Publicado: (2020)

Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study
por: Ohno, Yuko, et al.
Publicado: (2014)

Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
por: Tenenbaum, Alexander, et al.
Publicado: (2008)

Potential benefits of L. acidophilus in dyslipidemic rats
por: Reamtong, Onrapak, et al.
Publicado: (2021)

Dyslipidemic drugs in metabolic syndrome
por: Siddiqi, Sheelu S., et al.
Publicado: (2013)

Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo.
por: Mulligan, H. D., et al.
Publicado: (1991)

Bezafibrate for X-Linked Adrenoleukodystrophy
por: Engelen, Marc, et al.
Publicado: (2012)

Therapy of Canine Hyperlipidemia with Bezafibrate
por: De Marco, V., et al.
Publicado: (2017)

Comparison of Food and Nutrient Intakes between Japanese Dyslipidemic Patients with and without Low-Density Lipoprotein Cholesterol Lowering Drug Therapy: A Cross-Sectional Study
por: Kameyama, Noriko, et al.
Publicado: (2020)

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
por: Arbel, Yaron, et al.
Publicado: (2016)

Update on the use of fibrates: focus on bezafibrate
por: Goldenberg, Ilan, et al.
Publicado: (2008)

Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome
por: Lemche, A. V., et al.
Publicado: (2016)

The use of probiotics for improving lipid profiles in dyslipidemic individuals: an overview protocol
por: Fortes, Patricia M., et al.
Publicado: (2018)

Myocardial capillary density in normal and diabetic male rats: Effect of bezafibrate
por: Khazaei, M, et al.
Publicado: (2013)

Effects of citral on oxidative stress and hepatic key enzymes of glucose metabolism in streptozotocin/high-fat-diet induced diabetic dyslipidemic rats
por: Mishra, Chetna, et al.
Publicado: (2019)

Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on glucose tolerance and endothelial function - a crossover trial (AGENT)
por: Fukao, Kosuke, et al.
Publicado: (2011)

Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment
por: Node, Koichi, et al.
Publicado: (2009)

Antidiabetic Action of Bezafibrate in a Large Observational Database
por: Flory, James H., et al.
Publicado: (2009)

I-3 Treatment of CPT2 deficiency with bezafibrate
por: Laforet, P.
Publicado: (2011)

Bezafibrate prevents aging in in vitro-matured porcine oocytes
por: Kim, Ju-Yeon, et al.
Publicado: (2021)

Cardiac Mitochondria Dysfunction in Dyslipidemic Mice
por: Braczko, Alicja, et al.
Publicado: (2022)

Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats
por: Khazaei, M., et al.
Publicado: (2012)

OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism
por: Perttilä, Julia, et al.
Publicado: (2009)

Regulation of lipid metabolism-related gene expression in whole blood cells of normo- and dyslipidemic men after fish oil supplementation
por: Schmidt, Simone, et al.
Publicado: (2012)

Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Wang, Yu, et al.
Publicado: (2016)

Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)
por: Kinguchi, Sho, et al.
Publicado: (2019)

Investigation of novel material for effective photodegradation of bezafibrate in aqueous samples
por: Regulska, Elżbieta, et al.
Publicado: (2014)

Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Xu, Si-Chi, et al.
Publicado: (2017)

Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency
por: Suyama, Tomonori, et al.
Publicado: (2020)

Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice
por: Franko, Andras, et al.
Publicado: (2022)

Mass-Spectrometry-Based Lipidomics Discriminates Specific Changes in Lipid Classes in Healthy and Dyslipidemic Adults
por: Sánchez-Vinces, Salvador, et al.
Publicado: (2023)

Pharmacokinetic interaction of garlic and atorvastatin in dyslipidemic rats
por: Reddy, G. Dilip, et al.
Publicado: (2012)

Serum lysophospholipid levels are altered in dyslipidemic hamsters
por: Suárez-García, Susana, et al.
Publicado: (2017)

Addressing dyslipidemic risk beyond LDL-cholesterol
por: Tall, Alan R., et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients
por: Barakat, Lolwa, et al.
Publicado: (2013)

Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients
por: Bener, Abdulbari, et al.
Publicado: (2014)

Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice
por: Franko, Andras, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t2c6495vo45ckd4u2ncnvqidrm